Modelling of killer T-cell and cancer cell subpopulation dynamics under immuno- and chemotherapies

Show full item record



Permalink

http://hdl.handle.net/10138/313189

Citation

Halkola , A S , Parvinen , K , Kasanen , H , Mustjoki , S & Aittokallio , T 2020 , ' Modelling of killer T-cell and cancer cell subpopulation dynamics under immuno- and chemotherapies ' , Journal of Theoretical Biology , vol. 488 , 110136 . https://doi.org/10.1016/j.jtbi.2019.110136

Title: Modelling of killer T-cell and cancer cell subpopulation dynamics under immuno- and chemotherapies
Author: Halkola, Anni S.; Parvinen, Kalle; Kasanen, Henna; Mustjoki, Satu; Aittokallio, Tero
Contributor: University of Helsinki, Department of Clinical Chemistry and Hematology
University of Helsinki, HUS Comprehensive Cancer Center
University of Helsinki, Helsinki Institute for Information Technology
Date: 2020-03-07
Language: eng
Number of pages: 16
Belongs to series: Journal of Theoretical Biology
ISSN: 0022-5193
URI: http://hdl.handle.net/10138/313189
Abstract: Each patient’s cancer has a unique molecular makeup, often comprised of distinct cancer cell subpopulations. Improved understanding of dynamic processes between cancer cell populations is therefore critical for making treatment more effective and personalized. It has been shown that immunotherapy increases the survival of melanoma patients. However, there remain critical open questions, such as timing and duration of immunotherapy and its added benefits when combined with other types of treatments. We introduce a model for the dynamics of active killer T-cells and cancer cell subpopulations. Rather than defining the cancer cell populations based on their genetic makeup alone, we consider also other, non-genetic differences that make the cell populations either sensitive or resistant to a therapy. Using the model, we make predictions of possible outcomes of the various treatment strategies in virtual melanoma patients, providing hypotheses regarding therapeutic efficacy and side-effects. It is shown, for instance, that starting immunotherapy with a denser treatment schedule may enable changing to a sparser schedule later during the treatment. Furthermore, combination of targeted and immunotherapy results in a better treatment effect, compared to mono-immunotherapy, and a stable disease can be reached with a patient-tailored combination. These results offer better understanding of the competition between T-cells and cancer cells, toward personalized immunotherapy regimens.
Subject: 3122 Cancers
3111 Biomedicine
Combination therapy
Immunotherapy
Personalized medicine
Killer T-cells
Side-effects
DRUG-COMBINATIONS
PROLIFERATION
HETEROGENEITY
METASTATIC MELANOMA
EVOLUTION
THERAPY
RESISTANCE
LEUKEMIA
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S0022519319305053_main.pdf 1.527Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record